Novartis Statistics
Share Statistics
Novartis has 1.9B
shares outstanding. The number of shares has increased by -3.01%
in one year.
| Shares Outstanding | 1.9B |
| Shares Change (YoY) | -3.01% |
| Shares Change (QoQ) | -3.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 1.63M, so 0.08% of the outstanding
shares have been sold short.
| Short Interest | 1.63M |
| Short % of Shares Out | 0.08% |
| Short % of Float | 0.08% |
| Short Ratio (days to cover) | 26.18 |
Valuation Ratios
The PE ratio is 16.24 and the forward
PE ratio is null.
Novartis's PEG ratio is
-0.72.
| PE Ratio | 16.24 |
| Forward PE | n/a |
| PS Ratio | 3.75 |
| Forward PS | n/a |
| PB Ratio | 4.4 |
| P/FCF Ratio | 14.05 |
| PEG Ratio | -0.72 |
Financial Ratio HistoryEnterprise Valuation
Novartis has an Enterprise Value (EV) of 213.73B.
| EV / Sales | 4.13 |
| EV / EBITDA | 10.32 |
| EV / EBIT | 12.13 |
| EV / FCF | 15.48 |
Financial Position
The company has a current ratio of 1.04,
with a Debt / Equity ratio of 0.71.
| Current Ratio | 1.04 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 1.51 |
| Debt / FCF | 2.26 |
| Interest Coverage | 14.46 |
Financial Efficiency
Return on Equity is 27.11% and Return on Invested Capital is 15.55%.
| Return on Equity | 27.11% |
| Return on Assets | 11.68% |
| Return on Invested Capital | 15.55% |
| Revenue Per Employee | $681,601.94 |
| Profits Per Employee | $157,360.67 |
| Employee Count | 75,883 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 2.25 |
Taxes
| Income Tax | 1.7B |
| Effective Tax Rate | 12.47% |
Stock Price Statistics
The stock price has increased by 7.04% in the
last 52 weeks. The beta is 0.53, so Novartis's
price volatility has been higher than the market average.
| Beta | 0.53 |
| 52-Week Price Change | 7.04% |
| 50-Day Moving Average | 109.76 |
| 200-Day Moving Average | 107.58 |
| Relative Strength Index (RSI) | 49.45 |
| Average Volume (20 Days) | 55,296 |
Income Statement
In the last 12 months, Novartis had revenue of 51.72B
and earned 11.94B
in profits. Earnings per share was 5.92.
| Revenue | 51.72B |
| Gross Profit | 38.9B |
| Operating Income | 14.54B |
| Net Income | 11.94B |
| EBITDA | 20.71B |
| EBIT | 14.65B |
| Earnings Per Share (EPS) | 5.92 |
Full Income StatementBalance Sheet
The company has 11.46B in cash and 31.26B in
debt, giving a net cash position of -19.8B.
| Cash & Cash Equivalents | 11.46B |
| Total Debt | 31.26B |
| Net Cash | -19.8B |
| Retained Earnings | 46.46B |
| Total Assets | 102.25B |
| Working Capital | 1.01B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 17.62B
and capital expenditures -3.81B, giving a free cash flow of 13.8B.
| Operating Cash Flow | 17.62B |
| Capital Expenditures | -3.81B |
| Free Cash Flow | 13.8B |
| FCF Per Share | 6.84 |
Full Cash Flow StatementMargins
Gross margin is 75.2%, with operating and profit margins of 28.12% and 23.09%.
| Gross Margin | 75.2% |
| Operating Margin | 28.12% |
| Pretax Margin | 26.37% |
| Profit Margin | 23.09% |
| EBITDA Margin | 40.05% |
| EBIT Margin | 28.12% |
| FCF Margin | 26.69% |
